Genetic Tests for Antidepressants – CNS Dose

Peter ForsterBest Practices, GPS Update, Major Depression, Testing, Treatments of Depression Leave a Comment

About a year ago we reviewed the data on the use of genetic tests for antidepressants as well as other medications and identified three pharmacogenetic panels that seem to have research support: Genecept by Genomind, Genesight, and CNS Dose. Of these three we have been using Genecept and Genesight with some success but now we are happy to add to …

Functional Brain Imaging in Depression

Peter ForsterBasic Science, Best Practices, Major Depression, Psychobiology, Testing, Treatments of Depression

Is there a role for functional brain imaging in depression? Many people seeking treatment are interested in the notion that the brain imaging, particularly imaging that looks at neural activity, might be useful in guiding treatment. Up until the last couple of years the answer to this question has always been that the role is primarily restricted to research settings …

psychosis risk prediction

Psychosis Risk Prediction

Peter ForsterBest Practices, Diagnosis, Other Psychiatric Disorders Leave a Comment

Accurate psychosis risk prediction might allow us to provide early intervention and prevention services to young people at risk of developing psychosis. However our current tools for identifying those at risk are not able to accurately predict and identify those who might benefit from these services. A major step forward was the development of the concept of an At Risk …

Integrated Care

Peter ForsterAbout GPS, Best Practices

We have a passion for providing the most effective treatment at Gateway and that passion is illustrated by the efforts that we make to ensure that we deliver integrated care. Integrated care is a very simple idea. In fact it is probably something that you expect your treatment providers are already delivering. It means that the different providers who are …

Ketamine Guidelines

Peter ForsterBest Practices, Treatments of Depression

Ketamine guidelines have recently been published by American Psychiatric Association Council of Research Task Force on Novel Biomarkers and Treatments. They highlight what we know and what we don’t know about this treatment. What We Know “Several studies now provide evidence of ketamine hydrochloride’s ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant …

Motivational Interviewing for Change

Peter ForsterBest Practices, Physical Conditions and Health

We were inspired, as we often are, by the discussion in the most recent session of our bipolar 101 group to add some more content on our webpage about motivational interviewing and motivational enhancement therapy. These techniques are so often relevant to the people that we work with because mood disorders are frequently associated with difficult problems such as substance …

Neuroscience Based Nomenclature

Peter ForsterBest Practices, Psychobiology, Treatments of Depression

Neuroscience Based Nomenclature is an initiative by a number of prestigious organizations supporting research in neuroscience and psychiatry to change the way that we talk about psychotropic / psychiatric medications. Why this might be useful is illustrated by conversations that are likely familiar to all psychiatrists… A severely depressed patient with bipolar 1 is discussing her need for a change …